Funding for this research was provided by:
Association Belge contre les Maladies Neuro-Musculaires
Association Française contre les Myopathies
Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture
FSHD Global Research Foundation
Fonds De La Recherche Scientifique - FNRS
Received: 6 April 2017
Accepted: 27 December 2017
First Online: 12 January 2018
: CV, AT, SC, and AW contributed to this manuscript during their Ph.D. or post-doctoral studies in the Laboratory of Molecular Biology. The current position of CV, AT, SC, and AW are respectively at SGS (Belgium), Laboratory of Respiratory Physiology and Rehabilitation (Research Institute for Health Sciences and Technology) at the University of Mons, GSK (Belgium) and Straticell (Belgium).
: Primary human myoblasts were derived from muscle biopsies performed according to the current ethical and legislative rules of France, and written informed consent was obtained from all subjects, as directed by the ethical committee of CHU de Villeneuve (Montpellier, France) (Barro et al. 2010). In addition, the use of this material was approved by the ethics committee of the University of Mons (ref # A901) and the ethics committee of ULB-Erasme (Brussels ref. #B2011/003 and #P2015/516).
: Prof. Peter S. Zammit gave us permission to refer to the data his group presented at the FSHD International Research Consortium 2009, Boston, Massachusetts.Dr. Alexandre Philips (CRBM, CNRS, Montpellier), now retired from research, gave us permission to publish our collaborative study.
: The authors (CV, EA, FC, and AB) are inventors in a patent application for antisense agents useful in treating FSHD and targeting either DUX4 or DUX4c (EP patent # 242 62 03, published in the European Patent Bulletin (March 7 2012) and US patent # US20120225034 A, published on September 12, 2012.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.